Purinergic signaling in myocardial ischemia-reperfusion injury

Purinergic Signal. 2023 Mar;19(1):229-243. doi: 10.1007/s11302-022-09856-4. Epub 2022 Mar 7.

Abstract

Purines and their derivatives, extensively distributed in the body, act as a class of extracellular signaling molecules via a rich array of receptors, also known as purinoceptors (P1, P2X, and P2Y). They mediate multiple intracellular signal transduction pathways and participate in various physiological and pathological cell behaviors. Since the function in myocardial ischemia-reperfusion injury (MIRI), this review summarized the involvement of purinergic signal transduction in diversified pathological processes, including energy metabolism disorder, oxidative stress injury, calcium overload, inflammatory immune response, platelet aggregation, coronary vascular dysfunction, and cell necrosis and apoptosis. Moreover, increasing evidence suggests that purinergic signaling also mediates the prevention and treatment of MIRI, such as ischemic conditioning, pharmacological intervention, and some other therapies. In conclusion, this review exhibited that purinergic signaling mediates the complex processes of MIRI which shows its promising application and prospecting in the future.

Keywords: Cardioprotective interventions; Myocardial ischemia–reperfusion injury; Pathological processes; Purinergic signaling.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Coronary Vessels
  • Heart
  • Humans
  • Myocardial Reperfusion Injury* / metabolism
  • Myocardial Reperfusion Injury* / prevention & control
  • Oxidative Stress
  • Signal Transduction / physiology